Esegui ricerca
France, Medicine, Immunology, Health
Fighting resistance to antimalarial drug
Fighting resistance to antimalarial drug
When it comes to the emergence of antimalarial drug resistance, it’s not a question of ‘if’ but ‘when’.
Gordon Langsley – Focus on biological signalling to defeat malaria
Gordon Langsley – Focus on biological signalling to defeat malaria
Millions of people die each year of malaria – a disease transmitted by the Anopheles mosquito. There are major barriers in vaccine development as well as increased resistance to currently available therapies.
The fight against hepatitis C in Egypt
The fight against hepatitis C in Egypt
There is a hepatitis C epidemic in Egypt. Ironically, this is in large part due to a public health campaign in the 1960s and 1970s, during which injection needles were being re-used.
Camille Locht – an innovative solution to infant whooping cough
Camille Locht – an innovative solution to infant whooping cough
Scientists involved in the EU-funded project ChildInnovac are about to publish in the online journal Plos One the results of their first clinical trial of a new nasal vaccine.
Nasal vaccine: towards an alternative to injection for infants
Nasal vaccine: towards an alternative to injection for infants
Whooping cough and bronchiolitis are respiratory infections frequently affecting young children. In particular, infants under three months are very sensitive to these illnesses, which can lead to death in the most severe cases .
New Vaccine to Protect Babies from Whooping Cough
New Vaccine to Protect Babies from Whooping Cough
In Europe, whooping cough ( Pertussis ) is in the increase, with more than 20.000 cases reported annually . Often infants fall victim to the disease, where it can be life-threatening.
Nicolas Mouz - progressing towards an efficient HIV vaccine
Nicolas Mouz - progressing towards an efficient HIV vaccine
European researchers have designed two new vaccine candidates to fight the HIV virus. These have been developed within the EU-funded project EURONEUT 41 .
A HIV vaccine preventing healthy cells’ infection
A HIV vaccine preventing healthy cells’ infection
AIDS research has attempted many strategies to tackle the HIV virus infection. Now, a new type of vaccine developed within an EU-funded project, called EuroNeut-41 , is based on one of the envelope proteins of the HIV virus , called the gp41 protein.
New Hopes for an AIDS Vaccine
New Hopes for an AIDS Vaccine
HIV is still plaguing humanity with 35 million infected people worldwide. Antiretroviral drugs do slow down the progression of the disease but at a high cost and with long term toxicity.